Berkovitch Matitiahu, Diav-Citrin Orna, Greenberg Revital, Cohen Michal, Bulkowstein Mordechai, Shechtman Svetlana, Bortnik Oxana, Arnon Judy, Ornoy Asher
Clinical Pharmacology and Toxicology unit, Drug Consultation Centre, Assaf Harofeh Medical Centre, Zerifin, Israel.
Br J Clin Pharmacol. 2004 Sep;58(3):298-302. doi: 10.1111/j.1365-2125.2004.02138.x.
The number of published studies on the use of amoxycillin/clavulanic acid during pregnancy is small and so is the number of pregnancies investigated in those studies. In this study we wished to investigate prospectively the safety of intrauterine exposure to amoxycillin/clavulanic acid in a relatively large cohort of women.
Women treated (n = 191) with amoxycillin/clavulanic acid during the first trimester of pregnancy were recruited from two teratogen information centres in Israel. Exposed women were matched for age, smoking habits and alcohol consumption with 191 controls exposed to amoxycillin only for similar medical indications.
Maternal age, birth weight, gestational age at delivery, rates of live births and abortions were comparable between the two groups. Rates of major malformations in the amoxycillin/clavulanic acid group (3/158, 1.9%) did not differ significantly from controls (5/163, 3%) (P = 0.49, relative risk = 0.62, 95% confidence interval 0.15, 2.55), and were within the expected baseline risk for the general population.
These data suggest that exposure to amoxycillin/clavulanic acid during pregnancy is unlikely to be associated with an increased risk of malformations.
关于孕期使用阿莫西林/克拉维酸的已发表研究数量较少,且这些研究中所调查的妊娠案例数量也不多。在本研究中,我们希望前瞻性地调查相对大量女性群体宫内暴露于阿莫西林/克拉维酸的安全性。
从以色列的两个致畸物信息中心招募在妊娠早期接受阿莫西林/克拉维酸治疗的女性(n = 191)。将暴露组女性与191名因类似医学指征仅暴露于阿莫西林的对照组女性在年龄、吸烟习惯和饮酒量方面进行匹配。
两组之间的产妇年龄、出生体重、分娩时的孕周、活产率和流产率相当。阿莫西林/克拉维酸组的主要畸形率(3/158,1.9%)与对照组(5/163,3%)相比无显著差异(P = 0.49,相对风险 = 0.62,95%置信区间0.15,2.55),且在一般人群预期的基线风险范围内。
这些数据表明孕期暴露于阿莫西林/克拉维酸不太可能与畸形风险增加相关。